CBD Attenuated a Normal Cortisol Decline in a Historical Healthy-Volunteer Study
An early human CBD review describes attenuation of the normal decline in plasma cortisol after CBD. That result should not be relabeled as a demonstrated reduction in stress hormones.
The placebo trajectory helped define the finding
The review summarizes a crossover study involving 11 healthy volunteers. Plasma cortisol declined during placebo treatment, consistent with its normal daily rhythm. Oral CBD at 300 or 600 mg attenuated that decline. The comparison therefore concerned the trajectory of cortisol over the observation period, not simply whether a later value was lower than an earlier one.
Subjective sedation supplied another observation
Participants also reported a sedative effect. Sedation and cortisol are different endpoints, and neither should be used as a substitute for the other. The supplied review does not establish that the hormonal change caused the subjective effect or that either demonstrates a clinical benefit for a stress-related disorder.
Timing belongs beside the hormone result
Hormonal measurements that vary with time require an appropriate time-matched comparison. Without the placebo trajectory, a declining value could be misread as a treatment effect. This small historical experiment does not establish long-term endocrine safety, a treatment for adrenal disease or a personal CBD dose. It illustrates why the normal physiological pattern and the direction of the actual treatment comparison must remain explicit.
Related analysis: the broader review findings and limitations.
Research cited
This analysis draws on the supplied review. Individual studies are discussed as summarized there: Zhornitsky and Potvin (2012). Cannabidiol in Humans—The Quest for Therapeutic Targets.
